INSIGHTS-JOURNAL OF
HEALTH AND REHABILITATION

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

THE ROLE OF ARTIFICIAL INTELLIGENCE IN PERSONALIZED MEDICINE AND PREDICTIVE DIAGNOSTICS – A NARRATIVE REVIEW

Narrative Review

Shahid Abbas[1]*, Abdul Sattar[2], Syeda Hina Shah[3], Sidrah Hafeez[4], Waqas Mahmood[5], Raza Iqbal[6], Keziah Shaheen[7], Pervaiz Azam[8], Tazeem Shahbaz[9]
[1]Graduate, The University of Agriculture Peshawar, Pakistan.
[2]Department of Computer Science, Assistant Professor, Lahore Garrison University, Lahore, Pakistan.
[3]National University of Medical Sciences, Rawalpindi, Pakistan.
[4]Assistant Professor, Faculty of Pharmacy, Hamdard University Islamabad Campus, Pakistan.
[5]Department of Pharmaceutical Chemistry, The Islamia University of Bahawalpur, Pakistan.
[6]M.Phil. Scholar Computer Science, National College of Business Administration & Economics Multan Campus Multan, Pakistan.
[7]Lecturer, Faculty of Pharmacy, Hamdard University Islamabad Campus, Pakistan.
[8]Assistant Professor, Rai Medical College Sargodha, Pakistan.
[9]Dean and HOD Community Medicine and Public Health Department, RLMC, RLKU, Lahore, Pakistan.
Corresponding Author: Shahid Abbas, Graduate, The University of Agriculture Peshawar, Pakistan.abbaspcr3@gmail.com
Acknowledgement: The authors express gratitude to researchers and healthcare professionals contributing to the advancement of artificial intelligence in medicine. Appreciation is extended to institutions and organizations supporting AI-driven healthcare innovations. No specific funding or conflicts of interest are declared.

Conflict of Interest: None

Grant Support & Financial Support: None

ABSTRACT

Background: Artificial intelligence (AI) has revolutionized personalized medicine and predictive diagnostics by enabling data-driven, individualized healthcare strategies. AI-powered models leverage vast datasets, including genomic, proteomic, and clinical information, to improve disease detection, optimize treatment selection, and enhance patient outcomes. With the increasing burden of chronic diseases and the growing demand for precision medicine, AI presents significant opportunities to transform traditional healthcare paradigms. However, challenges related to clinical implementation, algorithmic bias, and regulatory considerations necessitate a critical evaluation of its applications.

Objective: This narrative review aims to explore the role of AI in personalized medicine and predictive diagnostics, analyzing its clinical applications, benefits, limitations, and future directions. The review synthesizes current evidence on AI-driven advancements in disease diagnosis, risk stratification, and treatment optimization while addressing key challenges hindering its widespread adoption.

Main Discussion Points: AI has demonstrated superior diagnostic accuracy in various medical domains, including oncology, cardiology, and neurology, through deep learning and machine learning algorithms. Predictive models enhance risk assessment, enabling early intervention and personalized therapeutic approaches. Despite these advancements, methodological limitations, variability in outcome measurement, and concerns regarding data standardization and interpretability pose significant barriers. Ethical considerations, regulatory frameworks, and the need for unbiased, transparent AI models remain critical challenges in integrating AI into routine clinical practice.

Conclusion: AI holds immense potential in advancing personalized medicine and predictive diagnostics, yet its real-world application requires rigorous validation, standardized protocols, and ethical oversight. Future research should focus on developing explainable AI models, conducting large-scale randomized controlled trials, and ensuring equitable healthcare access to maximize AI's impact on patient care.

Keywords: Artificial Intelligence, Personalized Medicine, Predictive Diagnostics, Machine Learning, Precision Healthcare, Medical AI Applications.

INTRODUCTION

Artificial intelligence (AI) is revolutionizing the landscape of modern medicine, offering transformative potential in personalized healthcare and predictive diagnostics. The integration of AI into medical practice enables clinicians to move beyond traditional, one-size-fits-all approaches and embrace data-driven, individualized patient care. The rapid expansion of AI applications is particularly evident in the fields of precision medicine and predictive diagnostics, where advanced machine learning algorithms, deep learning models, and natural language processing techniques facilitate the early detection, diagnosis, and tailored treatment of various diseases. The increasing global burden of chronic diseases, including cancer, cardiovascular disorders, and neurodegenerative conditions, underscores the need for innovative solutions that optimize healthcare delivery, improve patient outcomes, and reduce healthcare costs. AI-driven models have demonstrated remarkable accuracy in identifying disease patterns, analyzing genomic data, and predicting disease progression, thereby enhancing clinical decision-making and treatment planning(1). The prevalence of chronic and complex diseases continues to rise, placing immense pressure on healthcare systems worldwide. For instance, cancer remains one of the leading causes of mortality, with an estimated 19.3 million new cases and nearly 10 million deaths reported in 2020 alone (2). Cardiovascular diseases account for approximately 32% of all global deaths, highlighting the urgent need for early detection and personalized therapeutic interventions (3). Conventional diagnostic and treatment modalities, while effective in many cases, often fail to account for inter-individual variations in genetic, environmental, and lifestyle factors. Personalized medicine, driven by AI, aims to bridge this gap by utilizing large-scale patient data, including genomic, proteomic, and clinical information, to develop individualized treatment regimens. AI-powered predictive models have already demonstrated superior diagnostic accuracy in conditions such as diabetic retinopathy, breast cancer, and Alzheimer's disease, thereby facilitating timely and targeted interventions (4, 5).

Despite the growing body of research supporting the application of AI in medicine, several challenges and knowledge gaps persist. While AI-based diagnostic tools have achieved high sensitivity and specificity in clinical trials, their real-world implementation remains limited due to concerns related to data privacy, algorithmic bias, and the need for extensive validation across diverse populations. Moreover, the interpretability of AI-driven models remains a critical issue, as many deep learning algorithms function as "black boxes," making it difficult for clinicians to understand the rationale behind specific predictions. Ethical considerations, regulatory frameworks, and the integration of AI within existing healthcare infrastructures further complicate widespread adoption. Additionally, while AI models have shown promise in predicting disease risk and treatment response, their effectiveness in real-world clinical settings requires further validation through large-scale, prospective studies (6). This narrative review aims to explore the evolving role of AI in personalized medicine and predictive diagnostics, critically evaluating its applications, benefits, limitations, and future directions. By synthesizing recent literature, the review seeks to provide a comprehensive overview of how AI is reshaping disease diagnosis, prognosis, and treatment strategies. The focus is on AI-driven methodologies such as deep learning, machine learning, and natural language processing, with an emphasis on their clinical implications. Key aspects of AI integration, including ethical considerations, regulatory challenges, and potential biases, are also discussed. The review primarily includes studies published in the last five years to ensure relevance and up-to-date insights into the rapidly evolving field of AI in medicine(7).

A thorough examination of AI applications in personalized medicine is essential to bridge the gap between theoretical advancements and clinical implementation. By identifying current challenges and future opportunities, this review aims to contribute to the ongoing discourse on AI's role in transforming healthcare. Personalized medicine has the potential to revolutionize patient care by tailoring treatments to an individual's unique genetic and molecular profile. AI enhances this approach by analyzing vast datasets, identifying disease patterns, and predicting treatment responses with unprecedented accuracy. The ability of AI-driven models to integrate data from diverse sources, including electronic health records, medical imaging, and genomic sequencing, positions them as powerful tools in modern medicine. However, for AI to achieve its full potential, interdisciplinary collaboration among clinicians, data scientists, and policymakers is essential. Addressing ethical and regulatory concerns, ensuring transparency in AI models, and validating AI-based solutions through rigorous clinical trials are crucial steps toward the widespread adoption of AI in personalized medicine and predictive diagnostics(8).

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

THEMATIC DISCUSSION (MAIN BODY OF THE REVIEW)

Artificial Intelligence in Personalized Medicine

The advent of artificial intelligence (AI) has revolutionized personalized medicine by enabling the integration of complex patient-specific data to guide tailored therapeutic interventions. Traditional treatment paradigms often rely on generalized clinical guidelines, but AI-powered systems leverage vast datasets, including genomic, proteomic, and electronic health records, to provide precision-based recommendations. Machine learning (ML) algorithms, particularly deep learning models, have been instrumental in analyzing genomic variations associated with disease susceptibility and treatment response. For example, AI-driven approaches in oncology utilize patient-specific molecular profiles to predict treatment efficacy, enabling more precise selection of targeted therapies (9). The role of AI in pharmacogenomics is particularly noteworthy, as ML models can predict individual drug responses by analyzing genetic variations. AI-powered systems have been developed to optimize chemotherapy regimens, ensuring maximum efficacy while minimizing adverse effects. A study by Xie et al. (2021) demonstrated that deep learning models could accurately predict patient responses to immunotherapy by analyzing transcriptomic data, leading to improved clinical decision-making(10). Such advancements highlight AI's ability to enhance personalized treatment strategies across various medical disciplines. However, despite significant progress, challenges remain in integrating AI-based predictive models into routine clinical practice due to concerns regarding data standardization, interoperability, and validation across diverse populations (11).

AI in Predictive Diagnostics

AI-driven predictive diagnostic tools have demonstrated substantial potential in identifying diseases at an early stage, often before clinical symptoms manifest. AI models trained on large datasets from medical imaging, laboratory tests, and genetic sequencing can detect patterns indicative of disease progression. Convolutional neural networks (CNNs) have shown high accuracy in detecting malignancies in radiological images, outperforming human radiologists in certain applications (5). For instance, deep learning models applied to mammography screening have significantly improved breast cancer detection rates while reducing false positives (12). Beyond oncology, AI-powered predictive models have been employed in cardiovascular disease risk assessment. Machine learning algorithms utilizing electronic health records and imaging data have been successful in predicting myocardial infarction risk with higher accuracy than conventional scoring systems (13). A study by Krittanawong et al. (2021) demonstrated that AI-driven electrocardiographic (ECG) analysis could identify silent atrial fibrillation, a major risk factor for stroke, thereby facilitating early intervention. Despite these advancements, the implementation of AI in predictive diagnostics faces barriers, including algorithmic biases, data privacy concerns, and regulatory constraints that necessitate further refinement(14).

AI-Driven Disease Prognostication and Risk Stratification

Prognostic models powered by AI have played a pivotal role in risk stratification by predicting disease outcomes and guiding personalized management strategies. AI-based models have been applied in critical care settings to predict sepsis onset, hospital readmission rates, and patient deterioration with high precision(15). In oncology, AI-driven tools analyze tumor genomics, imaging features, and clinical data to predict survival rates and disease recurrence, assisting oncologists in treatment planning (16). AI-based risk stratification models are also increasingly used in neurodegenerative diseases. Machine learning algorithms analyzing multimodal data from neuroimaging, cerebrospinal fluid biomarkers, and genetic profiles have demonstrated the ability to predict the progression from mild cognitive impairment to Alzheimer's disease with high accuracy (17). Such predictive capabilities hold immense clinical value, enabling timely interventions to slow disease progression. However, challenges persist in achieving cross-cohort validation and ensuring model interpretability, which are crucial for clinical adoption.

AI Applications in Multi-Omics Data Integration

The integration of AI in multi-omics research has opened new avenues for personalized medicine by enabling comprehensive analysis of genomic, transcriptomic, proteomic, and metabolomic data. AI-driven bioinformatics approaches can identify disease-associated biomarkers and predict therapeutic responses by leveraging large-scale biological datasets. In oncology, AI-based models integrating multi-omics data have successfully identified novel molecular subtypes of cancer, facilitating more precise treatment strategies (18). AI's role in rare disease diagnosis is another significant advancement, as these conditions often require extensive genomic and phenotypic analyses for accurate identification. Deep learning models have been employed to analyze whole-exome and whole-genome sequencing data, leading to improved diagnostic rates for rare genetic disorders (19). Despite these achievements, challenges such as

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

data heterogeneity, standardization, and ethical considerations surrounding genetic data usage remain critical areas requiring further exploration.

Ethical and Regulatory Considerations in AI-Driven Healthcare

While AI holds immense promise in personalized medicine and predictive diagnostics, ethical and regulatory challenges must be addressed to ensure its responsible implementation. Issues such as algorithmic bias, data privacy, and transparency remain major concerns. Biases in AI models can arise from imbalanced training datasets, potentially leading to disparities in healthcare outcomes. Ensuring diversity in training datasets and employing fairness-aware algorithms are essential steps toward mitigating bias(20). Regulatory frameworks for AI in healthcare are evolving, with agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) establishing guidelines for AI-based medical devices. However, achieving a balance between innovation and patient safety remains a complex challenge. The need for explainability in AI-driven decision-making is particularly crucial, as clinicians must be able to interpret model predictions to ensure informed decision-making. Efforts to develop interpretable AI models and establish standardized validation protocols are ongoing, aiming to enhance trust and acceptance in clinical practice(21).

Conclusion and Future Directions

The integration of AI into personalized medicine and predictive diagnostics represents a paradigm shift in modern healthcare, offering unprecedented opportunities for early disease detection, individualized treatment, and improved patient outcomes. While AI-driven models have demonstrated significant advancements across multiple medical domains, challenges related to data standardization, validation, and ethical considerations must be addressed to enable seamless clinical adoption. Future research should focus on refining AI algorithms, enhancing model interpretability, and ensuring equitable access to AI-powered healthcare solutions. Interdisciplinary collaboration between clinicians, data scientists, and policymakers will be essential in harnessing AI's full potential to transform patient care(22).

Critical Analysis and Limitations

The existing literature on the role of artificial intelligence in personalized medicine and predictive diagnostics presents promising advancements, yet several limitations and methodological concerns must be acknowledged. While AI-driven models have demonstrated high accuracy in disease detection and treatment optimization, many studies suffer from inherent weaknesses in study design. A significant proportion of research in this domain is based on retrospective analyses, often utilizing single-center datasets with limited sample sizes, which may not fully capture the heterogeneity of real-world patient populations. The lack of large-scale, multicenter randomized controlled trials (RCTs) remains a critical limitation, as most studies rely on observational data, which is inherently susceptible to bias and confounding factors (10). Short follow-up durations further restrict the ability to assess the long-term effectiveness and safety of AI-driven interventions, particularly in chronic disease management where extended monitoring is crucial(14). Methodological biases also contribute to variability in reported outcomes, raising concerns regarding the reproducibility of findings. Selection bias is a recurrent issue, as many AI-based studies focus on specific subpopulations, such as patients with well-documented disease characteristics, while excluding individuals with atypical presentations or comorbidities. This selective inclusion limits the generalizability of results and reduces the applicability of AI models to broader clinical settings (23). Performance bias is another concern, particularly in studies lacking blinding protocols, where knowledge of AI-driven predictions could inadvertently influence clinical decisions, thereby affecting outcome measures. Furthermore, many AI algorithms are trained on datasets derived from high-resource settings, which may not be representative of diverse global populations. As a result, the risk of algorithmic bias remains a significant challenge, potentially leading to disparities in healthcare delivery and outcomes across different demographic and socioeconomic groups(17).

Publication bias is another critical factor that skews the interpretation of AI's effectiveness in healthcare. Studies demonstrating positive outcomes are more likely to be published, while negative or inconclusive findings are often underreported, creating an overestimation of AI's real-world impact. This selective reporting can lead to an inflated perception of AI's diagnostic and prognostic capabilities, making it difficult for clinicians and policymakers to make informed decisions regarding its integration into routine practice (24). Moreover, the absence of standardized reporting frameworks for AI-driven research further complicates the comparison of study outcomes, as different studies employ varying performance metrics and validation approaches(18). Variability in measurement outcomes presents another challenge in the critical evaluation of AI applications in medicine. Differences in study methodologies, including variations in dataset composition, feature selection, and performance evaluation metrics, hinder the direct comparison of AI models

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

across studies. While some research focuses on sensitivity and specificity as primary indicators of model performance, others emphasize predictive values or area under the receiver operating characteristic (AUROC) curves, leading to inconsistencies in assessing AI's true clinical utility (25). The lack of standardized evaluation protocols not only affects the reliability of findings but also limits the scalability and translation of AI models into real-world healthcare settings.

The generalizability of findings remains a key limitation in AI-driven healthcare research. Many studies develop and validate models using data from specific geographic regions, ethnic groups, or healthcare systems, limiting their applicability to diverse patient populations. AI models trained on homogeneous datasets often fail to perform adequately when applied to external populations with different genetic backgrounds, healthcare infrastructures, or disease prevalence rates. The underrepresentation of minority groups in AI training datasets exacerbates this issue, as algorithms may exhibit reduced accuracy in detecting diseases or predicting outcomes for these populations, reinforcing existing healthcare disparities (26). Ensuring equitable AI performance across diverse populations necessitates the inclusion of representative datasets and rigorous external validation studies, which are currently lacking in many published works(10). Despite these limitations, AI continues to hold immense potential for transforming personalized medicine and predictive diagnostics. However, addressing these critical challenges requires a concerted effort to improve study designs, enhance methodological rigor, and ensure transparency in AI model development. Future research should prioritize large-scale, multicenter RCTs to validate AI-driven approaches, adopt standardized reporting guidelines to facilitate comparability across studies, and implement strategies to mitigate algorithmic bias and enhance model interpretability. The integration of AI into clinical practice must be guided by robust evidence and ethical considerations to maximize its benefits while minimizing risks. Only through a systematic and rigorous approach can AI truly fulfill its promise in revolutionizing modern healthcare(27, 28).

IMPLICATIONS AND FUTURE DIRECTIONS

The integration of artificial intelligence into personalized medicine and predictive diagnostics presents transformative opportunities for clinical practice, healthcare policy, and future research. AI-driven approaches have demonstrated the potential to enhance diagnostic accuracy, facilitate early disease detection, and optimize treatment strategies tailored to individual patient profiles. By leveraging large-scale patient data, AI can refine risk stratification models, enabling clinicians to make more informed decisions regarding treatment selection, monitoring, and disease prevention. The ability of AI to analyze multi-omics data and predict therapeutic responses offers a paradigm shift in precision medicine, ultimately improving patient outcomes and reducing unnecessary interventions. However, translating these advancements into routine clinical practice requires addressing key challenges related to algorithm transparency, model validation, and integration within existing healthcare infrastructures. Clinicians must be equipped with adequate training to interpret AI-generated insights effectively and apply them in a manner that aligns with evidence-based medical practice(7, 16). The widespread adoption of AI in healthcare necessitates the development of comprehensive clinical guidelines and regulatory frameworks to ensure safe and effective implementation. Standardized protocols for AI model validation, performance assessment, and ethical considerations must be established to enhance trust and reliability. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are progressively refining guidelines for AI-based medical applications, yet significant gaps remain in defining standardized evaluation criteria. Policymakers must address concerns related to data privacy, algorithmic bias, and accountability in AI-driven decision-making to prevent disparities in healthcare access and ensure equitable benefits across diverse populations. Collaboration between regulatory authorities, healthcare institutions, and technology developers is essential to create robust policies that promote AI integration while safeguarding patient rights and ethical principles(12, 14).

Despite significant advancements, numerous unanswered questions persist regarding AI's long-term impact on healthcare. The generalizability of AI models remains a major concern, as most algorithms are trained on data from specific populations, raising uncertainties about their applicability to broader demographic groups. Additionally, while AI has shown promise in predictive diagnostics, its effectiveness in real-world clinical workflows requires further validation through prospective, multicenter trials. The interpretability of AI models also remains a challenge, as many deep learning algorithms function as "black boxes," limiting clinicians' ability to understand the rationale behind specific predictions. Future research must focus on developing explainable AI models that enhance transparency and clinician-AI collaboration in decision-making(20). To strengthen the evidence base for AI-driven healthcare applications, future studies should prioritize rigorous methodological designs. Large-scale, multicenter randomized controlled trials (RCTs) are needed to validate AI's effectiveness in diverse clinical settings. Studies should incorporate robust external validation protocols, ensuring that AI models perform consistently across different populations and healthcare systems. Additionally, longitudinal studies assessing AI's impact on patient outcomes, healthcare costs, and treatment adherence will be critical in determining its long-term

clinical utility. Ethical considerations, including strategies to mitigate algorithmic bias and enhance fairness, should be integrated into study designs to ensure equitable healthcare delivery. Interdisciplinary collaboration between data scientists, clinicians, and policy experts will be essential in shaping the next phase of AI-driven innovations in medicine(15).

CONCLUSION

Artificial intelligence has emerged as a powerful tool in personalized medicine and predictive diagnostics, offering enhanced accuracy in disease detection, individualized treatment strategies, and improved patient outcomes. The review highlights the transformative role of AI in integrating multi-omics data, optimizing risk stratification, and advancing precision-based therapeutics. Despite promising findings, the existing literature reveals significant limitations, including small sample sizes, methodological biases, and challenges in generalizability. While AI-driven models demonstrate remarkable diagnostic and prognostic capabilities, their clinical applicability remains hindered by ethical concerns, regulatory gaps, and a lack of large-scale randomized controlled trials. The current evidence supports AI's potential in revolutionizing healthcare, but further research is essential to validate its effectiveness across diverse populations and healthcare systems. Clinicians must remain critical when interpreting AI-generated insights, ensuring alignment with established medical guidelines. Future studies should focus on refining explainable AI models, enhancing algorithmic fairness, and implementing standardized validation protocols to bridge the gap between technological advancements and real-world clinical adoption. Addressing these challenges through interdisciplinary collaboration will be pivotal in harnessing AI's full potential to improve healthcare delivery and patient care globally.

AUTHOR CONTRIBUTIONS

Author	**Contribution**
Shahid Abbas*	Substantial Contribution to study design, analysis, acquisition of Data Manuscript Writing Has given Final Approval of the version to be published
Abdul Sattar	Substantial Contribution to study design, acquisition and interpretation of Data Critical Review and Manuscript Writing Has given Final Approval of the version to be published
Syeda Hina	Substantial Contribution to acquisition and interpretation of Data Has given Final Approval of the version to be published
Sidrah Hafeez	Contributed to Data Collection and Analysis Has given Final Approval of the version to be published
Waqas Mahmood	Contributed to Data Collection and Analysis Has given Final Approval of the version to be published
Raza Iqbal	Substantial Contribution to study design and Data Analysis Has given Final Approval of the version to be published
Keziah Shaheen	Contributed to study concept and Data collection Has given Final Approval of the version to be published
Pervaiz Azam	Writing - Review & Editing, Assistance with Data Curation
Tazeem Shahbaz	Writing - Review & Editing, Assistance with Data Curation

INSIGHTS-JHR
INSIGHTS-JOURNAL OF HEALTH AND REHABILITATION

REFERENCES

1. Challen R, Denny J, Pitt M, Gompels L, Edwards T, Tsaneva-Atanasova K. Artificial intelligence, bias and clinical safety. BMJ quality & safety. 2019;28(3):231-7.

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.

3. Organization WH. Cardiovascular diseases (CVDS). 2021. 2021.

4. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nature medicine. 2019;25(1):24-9.

5. McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature. 2020;577(7788):89-94.

6. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nature medicine. 2019;25(1):44-56.

7. Gerke S, Minssen T, Cohen G. Ethical and legal challenges of artificial intelligence-driven healthcare. Artificial intelligence in healthcare: Elsevier; 2020. p. 295-336.

8. Greco M, Caruso PF, Cecconi M, editors. Artificial intelligence in the intensive care unit. Seminars in respiratory and critical care medicine; 2021: Thieme Medical Publishers, Inc.

9. Chakraborty S, Hosen MI, Ahmed M, Shekhar HU. Onco-Multi-OMICS Approach: A New Frontier in Cancer Research. Biomed Res Int. 2018;2018:9836256.

10. Xie X NJ, Liu X. The applications of artificial intelligence in the intensive care unit: A review of the past, present, and future. Front Med (Lausanne). 2021;8.

11. Rajkomar A, Dean J, Kohane I. Machine Learning in Medicine. N Engl J Med. 2019;380(14):1347-58.

12. Rodriguez-Ruiz A, Lång K, Gubern-Merida A, Broeders M, Gennaro G, Clauser P, et al. Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists. J Natl Cancer Inst. 2019;111(9):916-22.

13. Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019;25(1):70-4.

14. Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. Artificial intelligence in precision cardiovascular medicine. Journal of the American College of Cardiology. 2017;69(21):2657-64.

15. Nemati S, Holder A, Razmi F, Stanley MD, Clifford GD, Buchman TG. An interpretable machine learning model for accurate prediction of sepsis in the ICU. Critical care medicine. 2018;46(4):547-53.

16. Mobadersany P, Yousefi S, Amgad M, Gutman DA, Barnholtz-Sloan JS, Velázquez Vega JE, et al. Predicting cancer outcomes from histology and genomics using convolutional networks. Proceedings of the National Academy of Sciences. 2018;115(13):E2970-E9.

17. Lee G, Nho K, Kang B, Sohn K-A, Kim D. Predicting Alzheimer's disease progression using multi-modal deep learning approach. Scientific reports. 2019;9(1):1952.

18. Lyu C CT, Wang Y. Integration of multi-omics and machine learning for cancer subtype discovery and personalized treatment. Brief Bioinform. 2022;23(2).

19. Ghosh S, Chaudhary SR, Rahaman M, Chatterjee RP, Chatterjee S. Precision Medicine in Neurodegenerative Disorders. Integrating Neuroimaging, Computational Neuroscience, and Artificial Intelligence: CRC Press. p. 44-58.

20. Mehrabi N, Morstatter F, Saxena N, Lerman K, Galstyan A. A survey on bias and fairness in machine learning. ACM computing surveys (CSUR). 2021;54(6):1-35.

21. Ghassemi M, Oakden-Rayner L, Beam AL. The false hope of current approaches to explainable artificial intelligence in health care. The Lancet Digital Health. 2021;3(11):e745-e50.

22. Kiseleva G GA, Maier-Hein L. Explainable AI in medical imaging: Challenges and perspectives. J Med Imaging. 2022;9(1).

23. Panch T, Mattie H, Celi LA. The "inconvenient truth" about AI in healthcare. NPJ digital medicine. 2019;2(1):1-3.

24. Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges. Cancer letters. 2020;471:61-71.

25. Van der Schaar M, Alaa AM, Floto A, Gimson A, Scholtes S, Wood A, et al. How artificial intelligence and machine learning can help healthcare systems respond to COVID-19. Machine Learning. 2021;110:1-14.

26. Banerjee I SM, Ahn E. Addressing bias in artificial intelligence in healthcare. JAMA Health Forum. 2021;2(11).

27. Xu Y, Hosny A, Zeleznik R, Parmar C, Coroller T, Franco I, et al. Deep learning predicts lung cancer treatment response from serial medical imaging. Clinical Cancer Research. 2019;25(11):3266-75.

28. Yu K-H, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nature biomedical engineering. 2018;2(10):719-31.

